MABION S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.14 PLN | -0.35% |
|
+3.50% | -5.56% |
| Apr. 16 | Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2024 * | 158M 38.84M | Sales 2025 * | 159M 39.17M | Capitalization | 278M 68.5M |
|---|---|---|---|---|---|
| Net income 2024 * | 11M 2.71M | Net income 2025 * | 13M 3.2M | EV / Sales 2024 * | 1.8 x |
| Net Debt 2024 * | 5.5M 1.36M | Net cash position 2025 * | 4.5M 1.11M | EV / Sales 2025 * | 1.72 x |
| P/E ratio 2024 * |
15.8
x | P/E ratio 2025 * |
14.1
x | Employees | 252 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.7% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.35% | ||
| 1 week | +3.50% | ||
| Current month | +5.15% | ||
| 1 month | +4.38% | ||
| 3 months | -9.79% | ||
| 6 months | -2.00% | ||
| Current year | -5.56% |
1 week
15.50
17.94
1 month
15.5017.94
Current year
15.5021.18
1 year
15.5023.60
3 years
15.50110.00
5 years
15.50126.20
10 years
15.50139.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | 50 | 18-12-31 | |
Slawomir Jaros
COO | Chief Operating Officer | - | 09-10-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Chairman | 58 | 17-06-13 | |
| Director/Board Member | 51 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.38% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 17.14 | -0.35% | 10 673 |
| 24-04-18 | 17.2 | -2.27% | 62,445 |
| 24-04-17 | 17.6 | +1.50% | 75,102 |
| 24-04-16 | 17.34 | +8.38% | 128,638 |
| 24-04-15 | 16 | -3.38% | 46,617 |
Delayed Quote Warsaw S.E., April 19, 2024 at 06:31 am EDT
More quotes
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
SELL
Number of Analysts
3
Last Close Price
17.2
PLN
Average target price
16.17
PLN
Spread / Average Target
-6.01%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.56% | 68.44M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.14% | 21.66B | |
| -18.35% | 20.77B | |
| -8.17% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- MAB Stock
